

**National Cancer Institute
Institutional Review Board
AGENDA
March 10, 2014
10/CRC 3-1608**

- 1. Review of Draft Minutes, February 24, 2014**
- 2. Announcements**
- 3. Old Business**
- 4. New Business**
- 5. Problem Report Forms**
- 6. Other Expedited Actions**
- 7. Continuing Reviews**
- 8. Amendment** 13C0106-B, "A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia" - Robert Kreitman, PI
- 9. Amendment** 08C0092-R, "A Phase I Study with an Expansion Cohort of the PARP Inhibitor AZD2281 (KU-0059436) Combined with Carboplatin in Breast and Ovarian Cancer in BRCA 1/2 Mutation Carriers (familial breast and ovarian cancer) and Sporadic Triple Negative Breast Cancer and Ovarian Cancer" - Jung-Min Lee, PI
- 10. Amendment** 13C0042-E, "A Phase I Study of XL184 (Cabozantinib, IND# 116059) in Children and Adolescents with Recurrent or Refractory Solid Tumors, Including CNS Tumors" - Brigitte Widemann, PI
- 11. Initial Review** P131409, "Evaluation of Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Genitourinary (Prostate, Bladder and Kidney) Cancers" - Baris Turkbey, PI